{
  "id": 15840961,
  "title": "Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance",
  "url": "https://urgent.news/2026/10/21/telix-pharma-reports-19-q3-revenue-growth-reaffirms-fy2026-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T02:44:07.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/telix-pharma-reports-19-q3-revenue-growth-reaffirms-fy2026-guidance"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}